文献速递乳腺乳腺X线

数字乳腺断层合成上结构扭曲且活检为非恶性病理的管理

Management of Architectural Distortion on Digital Breast Tomosynthesis With Nonmalignant Pathology at Biopsy.
PubMed 文献 · AJR Am J Roentgenol · 2022-02-02

本回顾性研究纳入2016年7月1日至2019年6月30日期间乳腺X线摄影(含数字2D和DBT)检出结构扭曲、影像引导穿刺活检为非恶性并接受手术切除的129例(125名女性)。活检为非恶性且一致的病例总体升级为恶性肿瘤率为10.2%(13/128),不典型增生者升级率2.2%(2/89),伴不典型增生者升级率28.2%(11/39)。结论认为DBT上结构扭曲伴活检一致非恶性病理可考虑影像随访。

要点

  • DBT上结构扭曲活检为非恶性且影像-病理一致时,手术升级为癌的总体率为10.2%(13/128)。
  • 活检无不典型增生的结构扭曲升级率低,为2.2%(2/89);伴不典型增生者升级率为28.2%(11/39)。
  • 年龄、乳腺癌个人史或家族史、筛查或诊断性摄影、乳腺密度、伴随X线表现、超声相关灶及活检方式与升级风险无显著关联(p > .05)。

核心结论

  • DBT上结构扭曲伴活检一致非恶性病理时,手术升级为恶性肿瘤的总体率为10.2%(13/128)。
  • 无不典型增生的结构扭曲升级率低,为2.2%(2/89)。
  • 作者认为,DBT上结构扭曲活检为无不典型增生的放射状瘢痕或其他一致良性病理时,可考虑影像随访。

研究设计与样本

  • 回顾性研究,纳入2016年7月1日至2019年6月30日期间乳腺X线摄影(数字2D乳腺摄影和DBT)检出结构扭曲、影像引导穿刺活检为非恶性并接受手术切除的129例(125名女性,平均年龄54岁,范围23-90岁)。
  • 活检病理中放射状瘢痕92例(71.3%),其他非恶性病理37例(28.7%)。
  • 采用描述性统计总结升级率,采用Pearson卡方检验和Wilcoxon符号秩检验比较升级与未升级病例的特征。

关键影像表现/征象

  • 影像数据提取自放射科报告,原文未报告具体影像征象细节。

诊断标准与关键数值

  • 活检无不典型增生的放射状瘢痕66例中,1例(1.5%)手术升级为导管原位癌(DCIS),无升级为浸润性癌。
  • 活检无不典型增生的良性病理24例中,1例被认为不一致;其余23例一致病例中,1例(4.3%)手术升级为DCIS,无升级为浸润性癌。
  • 活检一致非恶性病理的结构扭曲总体升级为癌率为10.2%(13/128)。
  • 无不典型增生的结构扭曲升级为癌率为2.2%(2/89),伴不典型增生者为28.2%(11/39)。

临床应用与阅片要点

  • 作者认为,DBT上结构扭曲活检为无不典型增生的放射状瘢痕或其他一致良性病理且无不典型增生时,可考虑影像随访。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Digital breast tomosynthesis (DBT) has led to increased detection and biopsy of architectural distortion, which may yield malignancy, radial scar, or other benign pathologies. Management of nonmalignant architectural distortion on DBT remains controversial. OBJECTIVE. The purpose of this study was to determine upgrade rates of architectural distortion on DBT from nonmalignant pathology at biopsy to malignancy at surgery. METHODS. This retrospective study included cases of mammographically detected architectural distortion from July 1, 2016, to June 30, 2019, that were nonmalignant at image-guided needle biopsy and underwent surgical excision. Mammographic examinations included digital 2D mammography and DBT. Imaging data were extracted from radiology reports. Upgrade rates were summarized using descriptive statistics. Features of upgraded and nonupgraded cases were compared using Pearson chi-square test and Wilcoxon signed rank test. RESULTS. The study included 129 cases of architectural distortion with nonmalignant pathology at biopsy that underwent excision in 125 women (mean age, 54 years; range, 23-90 years). At biopsy, 92 (71.3%) were radial scars and 37 (28.7%) were other nonmalignant pathologies. Of 66 radial scars without atypia at biopsy, one (1.5%) was upgraded to ductal carcinoma in situ (DCIS) at surgery and none to invasive cancer. Of 24 benign pathologies without atypia at biopsy, one was considered discordant. Of the 23 remaining concordant cases, one (4.3%) was upgraded to DCIS at surgery and none to invasive cancer. The overall upgrade rate to cancer of architectural distortion with concordant nonmalignant pathology at biopsy was 10.2% (13/128). The upgrade rate to cancer of architectural distortion without atypia was 2.2% (2/89) and with atypia was 28.2% (11/39). Explored features (age, personal or family breast cancer history, presentation by screening vs diagnostic mammography, breast density, associated mammographic findings, presence and size of ultrasound correlate, biopsy modality) showed no signifi-cant associations with upgrade risk (p > .05). CONCLUSION. Architectural distortion on DBT with concordant nonmalignant pathology at biopsy has an overall upgrade rate to malignancy at surgery of 10.2%. Architectural distortion without atypia has a low upgrade rate of 2.2%. CLINICAL IMPACT. Imaging surveillance can be considered for architectural distortion on DBT yielding radial scar without atypia or other concordant benign pathologies without atypia at biopsy.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Villa-Camacho, Bahl. Management of Architectural Distortion on Digital Breast Tomosynthesis With Nonmalignant Pathology at Biopsy. AJR Am J Roentgenol. 2022. PMID: 35107312. doi:10.2214/AJR.21.27161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。